Aduro Biotech (ADRO) Will Present Strong ADU-5100 Preclinical Data at ESMO Symposium
- Stocks close with gains, led by Dow as investors look for rate insight
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Robinhood (HOOD) rises after saying it plans to launch a credit card for US consumers
- Short sellers target Reddit shares as stock slips
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100
November 7, 2016 8:00 AM ESTBERKELEY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO) today highlighted an oral presentation given by the companys chief scientific officer, Thomas Dubensky Jr., Ph.D., at the 4th European Society of Medical Oncology (ESMO) Symposium on Immuno-Oncology held last week in Lausanne, Switzerland. The data, generated from multiple preclinical models, demonstrated important changes in the tumor microenvironment and the activation of acute and systemic tumor-specific immune cell responses following intratumoral administration of ADU-S100 (also known as MIW815), an investigational STING (Stimulator of Interferon Genes) Pathway Activator immunotherapy. Importantly, these... More